$ACOG

Alpha Cognition Inc. (ACOG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Alpha Cognition Inc. (ACOG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001655923 A1 00-0000000 0001655923 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Original reporting
Published Jun 23, 2026, 2:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ACOG
Neutral
medium confidence
Mentioned
$ACOG
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The newest disclosed facts are: (1) Dr. Robert Wills appointed non-executive Chair, replacing Len Mertz (not re-elected), and (2) director slate elected (6 directors) plus ratification of CBIZ CPAs P.C. as independent auditor.

02

Market read

This is a governance update with meeting-vote confirmation; it is unlikely to drive valuation without additional strategy/compensation details beyond what’s shown.

03

What to watch

Traders should check whether the 8-K includes (or is accompanied by) additional exhibits/press releases detailing compensation terms or strategic changes; this scrape only shows the headline items and voting results.

Relevance 6/10Novelty 4/10Timing: immediately after June 16, 2026 annual meeting; filed June 23, 2026

Background

The company filed an SEC Form 8-K covering board/officer changes and the results of its June 16, 2026 stockholder meeting.

Company-level read

Ticker impact

$ACOGNeutralMedium confidence
Context

Alpha Cognition appointed Dr. Robert Wills as non-executive Chair after Len Mertz did not stand for re-election at the June 16, 2026 meeting.

Expected impact

Low likelihood of a sustained move based solely on this filing; any reaction would be limited to governance sentiment.

Evidence & confidence

The filing discloses a chair appointment and director election/ratification of auditor, but provides no new financial guidance, deal terms, or operational commitments.

Market effects

No sector read-across; this is company-specific governance/board composition disclosure.

None indicated.

None indicated.

Counterpoint

The chair change could signal internal governance or strategic redirection, but the 8-K text here omits any rationale or plan, so the market may overreact initially.

Key entities

  • Alpha Cognition Inc.

    Nasdaq-listed company filing the 8-K; subject of the board/officer and meeting-vote disclosures.

  • Dr. Robert Wills

    Appointed non-executive Chair of the Board on June 16, 2026.

  • Len Mertz

    Did not stand for re-election; vacancy filled by Dr. Wills.

  • CBIZ CPAs P.C.

    Ratified as independent registered public accounting firm for the ensuing year.

Related articles

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

$SKHYMed

SK Hynix’s $38 billion buildout has a name attached: Nvidia

SK Hynix (SKHY) approved about 54.3 trillion won (about $38.3B) for two memory plants through 2031, Reuters reported. About 35.2 trillion won funds a DRAM fab in Yongin (Y2) with construction starting July 2027 and first cleanroom June 2029. Remaining 19.1 trillion won supports a NAND plant in Cheongju. Reuters also said it is reviewing further shareholder returns.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.